REAL-WORLD EVIDENCE IN ASIA PACIFIC- ARE WE READY? IS IT HELPFUL FOR DECISION MAKERS?
Author(s)
Kinwei Arnold Chan, MD, ScD, FISPE , Director, Health Data Research Center, National Taiwan University, Department of Medical Research, and Director, Clinical Trial Center, National Taiwan University Hospital, Taipei, Taiwan; Manabu Akazawa, PhD, MPH , Professor, Public Health and Epidemiology Department, Meiji Pharmaceutical University, Tokyo, Japan; Bart Barefoot, Director & VEO , Real World Evidence Policy and Advocacy, Value Evidence and Outcomes (VEO), Global Medical, GlaxoSmithKline, London, UK; Xin Sun, PhD , Professor & Director, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
Presentation Documents
Real-world evidence (RWE) is now commonly used to inform drug pricing and reimbursement decisions in Europe and North America. There also are ongoing efforts to incorporate RWE into drug development and regulatory processes in these regions. Recent years have seen an increasing interest in the use of RWE in Asia Pacific. However, the extent that RWE is embraced varies from country to country for many reasons, such as lack of data, poor data quality, data security, and privacy issues. How ready are we for RWE? Where are we now and where are we heading? In this plenary, speakers from various sectors will share their perspectives and valuable insights on the use of RWE, and address barriers impeding its use.
Conference/Value in Health Info
2018-09, ISPOR Asia Pacific 2018, Tokyo, Japan
Code
PL2
Topic
Health Policy & Regulatory, Real World Data & Information Systems